STORM Therapeutics presents breakthrough data showing in vivo efficacy and therapeutic proof of concept for targeting RNA modifying enzymes

Data to be presented at inaugural STORM Therapeutics RNA Epigenetics in Human Disease Conference in Cambridge, UK

18 September 2019, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies modulating RNA epigenetics announces today that Oliver Rausch, Chief Scientific Officer of STORM Therapeutics will present first of its kind data on targeting RNA modifying enzymes for cancer treatment at its inaugural “RNA Epigenetics in Human Disease Conference” taking place at St Catharine’s College, Cambridge, UK on 17-20 September 2019. Attendees are from renowned academic research institutions and pharmaceutical and biotechnology companies worldwide.

The presentation will take place at 12:00 BST today, Wednesday 18th September and is entitled “Targeting RNA modifying enzymes for the treatment of cancer”.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH